Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced the appointment of Alan Bash as the President of CARVYKTI®. In this newly established position, Mr. Bash will oversee the ongoing growth of CARVYKTI®, managing Legend Biotech’s commercial, technical operations, and quality functions related to the franchise.
“This expansion of our leadership team follows CARVYKTI’s recent successes, including approvals from the U.S. Food and Drug Administration and the European Commission for label expansion,” stated Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “We are pleased to welcome Alan and are confident that his extensive operational expertise in oncology will further enhance the Company’s leadership in the treatment of multiple myeloma.”
Mr. Bash brings a wealth of experience, having previously served as Chief Executive Officer for two oncology-focused biotech firms, most recently at ZielBio, and prior to that, as President and CEO at Checkmate Pharmaceuticals. He also spent 23 years at Bristol Myers Squibb, where he held various leadership roles across major therapeutic areas, including oncology, and played a pivotal role in the U.S. launch of Opdivo® as well as the expansion of other cancer treatments like Yervoy® and Erbitux®. He contributed to several blockbuster collaborations, including Abilify® with Otsuka and Eliquis® with Pfizer.
“CARVYKTI is the fastest launched CAR-T product on the market, and it has already gained impressive momentum,” said Mr. Bash. “I am eager to support the continued success of the CARVYKTI franchise and to collaborate with the Legend Biotech team and our partner, Johnson & Johnson, to unlock CARVYKTI’s potential to transform the treatment landscape for multiple myeloma.”
Mr. Bash holds a B.A. from Georgetown University and an M.B.A. from Columbia Business School.
